# Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC

> **NCT07018947** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fundacion Clinic per a la Recerca Biomédica** · enrollment: 90 (estimated)

## Conditions studied

- Resectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** Atezolizumab and Bevacizumab

## Key facts

- **NCT ID:** NCT07018947
- **Lead sponsor:** Fundacion Clinic per a la Recerca Biomédica
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11
- **Primary completion:** 2030-11
- **Final completion:** 2030-11
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07018947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07018947, "Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07018947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*